233 related articles for article (PubMed ID: 27627083)
1. [Type 2 diabetes mellitus and heart failure].
Linhart A; Bělohlávek J
Vnitr Lek; 2016; 62(7-8):592-7. PubMed ID: 27627083
[TBL] [Abstract][Full Text] [Related]
2. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
Scheen AJ
Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
[TBL] [Abstract][Full Text] [Related]
3. [Are some antidiabetic drugs also drugs useful for heart failure treatment?].
Murín J
Vnitr Lek; 2016 Apr; 62(4):322-8. PubMed ID: 27250612
[TBL] [Abstract][Full Text] [Related]
4. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
[TBL] [Abstract][Full Text] [Related]
6. Heart failure: SGLT2 inhibitors and heart failure -- clinical implications.
Raz I; Cahn A
Nat Rev Cardiol; 2016 Apr; 13(4):185-6. PubMed ID: 26961066
[TBL] [Abstract][Full Text] [Related]
7. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
8. Impact of empagliflozin in patients with diabetes and heart failure.
Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ
Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
[TBL] [Abstract][Full Text] [Related]
9. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
10. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L
Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
[TBL] [Abstract][Full Text] [Related]
11. EMPA-REG OUTCOME: The Cardiologist's Point of View.
Pham SV; Chilton R
Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
[TBL] [Abstract][Full Text] [Related]
12. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
Luconi M; Raimondi L; Di Franco A; Mannucci E
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1071-1078. PubMed ID: 27776917
[TBL] [Abstract][Full Text] [Related]
13. EMPA-REG OUTCOME: The Cardiologist's Point of View.
Pham SV; Chilton RJ
Am J Cardiol; 2017 Jul; 120(1S):S53-S58. PubMed ID: 28606345
[TBL] [Abstract][Full Text] [Related]
14. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
Scheen AJ; Delanaye P
Diabetes Metab; 2017 Apr; 43(2):99-109. PubMed ID: 28153377
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
Rajasekeran H; Lytvyn Y; Cherney DZ
Kidney Int; 2016 Mar; 89(3):524-6. PubMed ID: 26880444
[TBL] [Abstract][Full Text] [Related]
17. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
Scheen AJ
Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271
[TBL] [Abstract][Full Text] [Related]
18. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
Tanaka A; Node K
J Cardiol; 2017 Mar; 69(3):501-507. PubMed ID: 28043708
[TBL] [Abstract][Full Text] [Related]
19. Diabetes Mellitus and Heart Failure.
Lehrke M; Marx N
Am J Med; 2017 Jun; 130(6S):S40-S50. PubMed ID: 28526183
[TBL] [Abstract][Full Text] [Related]
20. Diabetes Mellitus and Heart Failure.
Lehrke M; Marx N
Am J Cardiol; 2017 Jul; 120(1S):S37-S47. PubMed ID: 28606342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
